Arezou Khosroshahi

12.9k total citations · 5 hit papers
54 papers, 4.9k citations indexed

About

Arezou Khosroshahi is a scholar working on Rheumatology, Epidemiology and Surgery. According to data from OpenAlex, Arezou Khosroshahi has authored 54 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Rheumatology, 22 papers in Epidemiology and 21 papers in Surgery. Recurrent topics in Arezou Khosroshahi's work include IgG4-Related and Inflammatory Diseases (31 papers), Neuroendocrine Tumor Research Advances (19 papers) and Gastrointestinal disorders and treatments (18 papers). Arezou Khosroshahi is often cited by papers focused on IgG4-Related and Inflammatory Diseases (31 papers), Neuroendocrine Tumor Research Advances (19 papers) and Gastrointestinal disorders and treatments (18 papers). Arezou Khosroshahi collaborates with scholars based in United States, Japan and United Kingdom. Arezou Khosroshahi's co-authors include John H. Stone, Vikram Deshpande, Mollie N. Carruthers, Donald B. Bloch, James R. Stone, Zachary S. Wallace, Sebastian Unizony, Suresh T. Chari, G. Petur Nielsen and Shweta Shinagare and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The Journal of Experimental Medicine.

In The Last Decade

Arezou Khosroshahi

52 papers receiving 4.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rituximab for IgG4-related disease: a prospective, open-label trial

2015 444 citations Mollie N. Carruthers, Arezou Khosroshahi et al. Annals of the Rheumatic Diseases profile →
The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease

2019 409 citations Zachary S. Wallace, Ray Naden et al. Annals of the Rheumatic Diseases profile →
Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4‐related systemic disease

2010 402 citations Arezou Khosroshahi, Donald B. Bloch et al. profile →
The diagnostic utility of serum IgG4 concentrations in IgG4-related disease

2014 373 citations Mollie N. Carruthers, Arezou Khosroshahi et al. Annals of the Rheumatic Diseases profile →
Rituximab for the Treatment of IgG4-Related Disease

2011 350 citations Arezou Khosroshahi, Mollie N. Carruthers et al. Medicine profile →

Peers

Countries citing papers authored by Arezou Khosroshahi

Since Specialization

Citations

This map shows the geographic impact of Arezou Khosroshahi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arezou Khosroshahi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arezou Khosroshahi more than expected).

Fields of papers citing papers by Arezou Khosroshahi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arezou Khosroshahi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arezou Khosroshahi. The network helps show where Arezou Khosroshahi may publish in the future.

Co-authorship network of co-authors of Arezou Khosroshahi

This figure shows the co-authorship network connecting the top 25 collaborators of Arezou Khosroshahi. A scholar is included among the top collaborators of Arezou Khosroshahi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arezou Khosroshahi. Arezou Khosroshahi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Unlocking disease insights to facilitate drug development: Pharmaceutical industry–academia collaborations in inflammation and immunology 2025 ·Drug Discovery Today ·Elena Peeva, Emma Guttman‐Yassky, Yuji Yamaguchi, Brian Berman, Barry S. Oemar, Jyoti Ramakrishna, Alessio Fasano, Carmella Evans‐Molina, Myron Chu, Benjamin Ungar, Pércío S. Gulko, María Padilla, (unknown), Arezou Khosroshahi, Patrick M. Brunner, (unknown), Michael S. Vincent, Mikael Dolsten	1
2	Multi-centered clinical validation demonstrating superior precision in lupus diagnosis: T cell autoantibodies and TC4d outperform conventional lupus erythematosus biomarkers 2025 ·Frontiers in Immunology ·Vasileios C. Kyttaris, Daniel J. Wallace, Arezou Khosroshahi, Andrew L. Concoff, Nicole Wilson, C C Liu, Susan Manzi, Joseph M. Ahearn, Seyed Alireza Taghavi, (unknown), (unknown), (unknown), (unknown), (unknown)	2
3	Multiplicative Impact of Adverse Social Determinants of Health on Outcomes in Lupus Nephritis: A Meta‐analysis and Systematic Review 2024 ·Arthritis Care & Research ·Shivani Garg, (unknown), (unknown), (unknown), Theresa L. Walunas, Rosalind Ramsey‐Goldman, Arezou Khosroshahi, Brad C. Astor, S. Sam Lim, Christie M. Bartels	10
4	Outcomes of COVID-19 in a cohort of pediatric patients with rheumatic diseases 2021 ·Pediatric Rheumatology ·(unknown), Christina A. Rostad, Kelly Rouster‐Stevens, Arezou Khosroshahi, Shanmuganathan Chandrakasan, Sampath Prahalad	16
5	Clinical course and outcomes of COVID-19 in rheumatic disease patients: a case cohort study with a diverse population 2021 ·Clinical Rheumatology ·(unknown), (unknown), Julie M. Shabto, Ghazala O’Keefe, Arezou Khosroshahi	17
6	The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease breakdown → 2019 ·Annals of the Rheumatic Diseases ·Zachary S. Wallace, Ray Naden, Suresh T. Chari, Hyon K. Choi, (unknown), (unknown), Phillip A. Hart, Dai Inoue, Mitsuhiro Kawano, Arezou Khosroshahi, Marco Lanzillotta, Kazuichi Okazaki, Cory A. Perugino, Amita Sharma, Takako Saeki, N. Schleinitz, Naoki Takahashi, Hisanori Umehara, Yoh Zen, James R. Stone	409
7	A 55‐Year‐Old Male Presenting With Altered Mental Status: A Complicated Case of Intracranial Aneurysm 2017 ·Arthritis Care & Research ·Shivani Garg, Arezou Khosroshahi	2
8	The diagnostic utility of serum IgG4 concentrations in IgG4-related disease breakdown → 2014 ·Annals of the Rheumatic Diseases ·Mollie N. Carruthers, Arezou Khosroshahi, (unknown), Vikram Deshpande, John H. Stone	373
9	IgG4-Related Disease and Hypertrophic Pachymeningitis 2013 ·Medicine ·Zachary S. Wallace, Mollie N. Carruthers, Arezou Khosroshahi, Robert Carruthers, Shweta Shinagare, Anat Stemmer‐Rachamimov, Vikram Deshpande, John H. Stone	137
10	Tocilizumab for the treatment of large‐vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica 2012 ·Arthritis Care & Research ·Sebastian Unizony, (unknown), Eli M. Miloslavsky, Sheila L. Arvikar, Arezou Khosroshahi, (unknown), James R. Stone, John H. Stone	199
11	IgG4-Related Systemic Disease as a Cause of “Idiopathic” Orbital Inflammation, Including Orbital Myositis, and Trigeminal Nerve Involvement 2011 ·Survey of Ophthalmology ·Zachary S. Wallace, Arezou Khosroshahi, Frederick A. Jakobiec, Vikram Deshpande, Mark P. Hatton, (unknown), Judith A. Ferry, John H. Stone	102
12	Rituximab for the Treatment of IgG4-Related Disease breakdown → 2011 ·Medicine ·Arezou Khosroshahi, Mollie N. Carruthers, Vikram Deshpande, Sebastian Unizony, Donald B. Bloch, John H. Stone	350
13	The latest on IgG4-RD 2011 ·Current Opinion in Rheumatology ·Mollie N. Carruthers, John H. Stone, Arezou Khosroshahi	76
14	Treatment approaches to IgG4-related systemic disease 2010 ·Current Opinion in Rheumatology ·Arezou Khosroshahi, John H. Stone	184
15	A 44‐year‐old woman with cutaneous bullae and extensive skin necrosis 2010 ·Arthritis Care & Research ·Brittany Lee, John H. Stone, (unknown), Arezou Khosroshahi	8
16	A clinical overview of IgG4-related systemic disease 2010 ·Current Opinion in Rheumatology ·Arezou Khosroshahi, John H. Stone	232
17	Riedel's Thyroiditis and Multifocal Fibrosclerosis are part of the IgG4‐related systemic disease spectrum 2010 ·Arthritis Care & Research ·(unknown), Arezou Khosroshahi, G. Petur Nielsen, Vikram Deshpande, John H. Stone	210
18	Painless jaundice with serial multi-organ dysfunction 2009 ·The Lancet ·Arezou Khosroshahi, James R. Stone, Daniel S Pratt, Vikram Deshpande, John H. Stone	29
19	Differential Role of Programmed Death-Ligand 1 and Programmed Death-Ligand 2 in Regulating the Susceptibility and Chronic Progression of Experimental Autoimmune Encephalomyelitis 2006 ·The Journal of Immunology ·Bing Zhu, Indira Guleria, Arezou Khosroshahi, Tanuja Chitnis, Jaime Imitola, Miyuki Azuma, Hideo Yagita∥, Mohamed H. Sayegh, Samia J. Khoury	100
20	A critical role for the programmed death ligand 1 in fetomaternal tolerance 2005 ·The Journal of Experimental Medicine ·Indira Guleria, Arezou Khosroshahi, Mohammed Javeed Ansari, Antje Habicht, Miyuki Azuma, Hideo Yagita, Randolph J. Noelle, Anthony J. Coyle, Andrew L. Mellor, Samia J. Khoury, Mohamed H. Sayegh	344

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact